7,688.62

+119.70

+1.58%

53,356.12

+1,569.40

+3.03%

25,736.51

+364.50

+1.44%

2,856.95

+44.50

+1.58%

4.8940

-0.0580

-1.17%

16.61

-4.22

-20.26%

4,070.70

+130.30

+3.31%

80,209.39

+2,430.06

+3.12%

Crude Oil Dec 26

88.09

-8.00

-8.33%

US Private Equity

10,855.23

+18.94

+0.17%

NasdaqCM - Delayed Quote USD

HCW Biologics Inc. (HCWB)

1.0800 -0.0700 (-6.09%)

At close: 4:00:00 PM EST

Loading Chart for HCWB

Chart Range Bar

Interval:

In partnership with ChartIQ

HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors

HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors

HCW Biologics Announces Pricing of $1.5 Million Private Placement

HCW Biologics Announces Pricing of $1.5 Million Private Placement

HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent

HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

Mobilize your Website

View Site in Mobile | Classic

Share by: